(Q34618210)

English

Pharmacokinetics, pharmacodynamics, and tolerability of aleglitazar in patients with type 2 diabetes: results from a randomized, placebo-controlled clinical study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

3 August 2017

Pharmacokinetics, pharmacodynamics, and tolerability of aleglitazar in patients with type 2 diabetes: results from a randomized, placebo-controlled clinical study (English)

1 reference

Europe PubMed Central

3 August 2017

0 references

type 2 diabetes

0 references

pharmacokinetics

1 reference

based on heuristic

inferred from title

pharmacodynamics

1 reference

based on heuristic

inferred from title

author name string

P Sanwald-Ducray

1

1 reference

Europe PubMed Central

3 August 2017

X Liogier D'ardhuy

2

1 reference

Europe PubMed Central

3 August 2017

C Jamois

3

1 reference

Europe PubMed Central

3 August 2017

L Banken

4

1 reference

Europe PubMed Central

3 August 2017

language of work or name

0 references

publication date

24 March 2010

1 reference

Europe PubMed Central

3 August 2017

Clinical Pharmacology & Therapeutics

1 reference

Europe PubMed Central

3 August 2017

88

1 reference

Europe PubMed Central

3 August 2017

2

1 reference

Europe PubMed Central

3 August 2017

197-203

1 reference

Europe PubMed Central

3 August 2017

https://scigraph.springernature.com/pub.10.1038/clpt.2009.259

0 references

The evolving diabetes burden in the United States

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.259

21 January 2018

Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.259

21 January 2018

The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women: 20 years of follow-up

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.259

21 January 2018

Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.259

21 January 2018

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.259

21 January 2018

Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.259

21 January 2018

Effects of intensive glucose lowering in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.259

21 January 2018

Intensive glycemic control and cardiovascular disease observations from the ACCORD study: now what can a clinician possibly think?

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.259

21 January 2018

The mechanisms of action of PPARs

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.259

21 January 2018

Therapeutic roles of peroxisome proliferator-activated receptor agonists

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.259

21 January 2018

Aleglitazar, a new, potent, and balanced dual PPARalpha/gamma agonist for the treatment of type II diabetes

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.259

21 January 2018

PPAR dual agonists: are they opening Pandora's Box?

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.259

21 January 2018

Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.259

21 January 2018

Safety considerations with fibrate therapy

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.259

21 January 2018

Effect of tesaglitazar, a dual PPAR alpha/gamma agonist, on glucose and lipid abnormalities in patients with type 2 diabetes: a 12-week dose-ranging trial.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.259

21 January 2018

Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.259

21 January 2018

Thiazolidinediones, Peripheral Edema, and Type 2 Diabetes: Incidence, Pathophysiology, and Clinical Implications

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.259

21 January 2018

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.259

21 January 2018

Intensive glycemic control in the ACCORD and ADVANCE trials

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.259

21 January 2018

Standards of medical care in diabetes--2009.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.259

7 January 2021

based on heuristic

inferred from DOI database lookup

Trends in cardiovascular complications of diabetes

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.259

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.259

7 January 2021

based on heuristic

inferred from DOI database lookup

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.259

7 January 2021

based on heuristic

inferred from DOI database lookup

Images in clinical medicine. Paget's disease of the mandible

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.259

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/CLPT.2009.259

1 reference

Europe PubMed Central

3 August 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

3 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34618210&oldid=2143956539"